ストックスクリーナーアプリを入手
91.48
0.09%
-0.08
アフターアワーズ：
91.80
0.32
+0.35%
Biontech Se Adr (BNTX) 最新ニュース
Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight - GlobeNewswire Inc.
BioNTech's Balancing Act: Plant Closures, Founders' Exit, and a Bet on Six Key Cancer Studies - aktiencheck.de
BioNTech’s Triple Transformation: Shuttering Plants, Losing Founders, and Banking on 15 Cancer Trials - aktiencheck.de
SK Hynix readies U.S. market debut as NATO strains and Gulf shipping risks unsettle investors - Traders Union
Cathie Wood Scoops Up SpaceX Shares Again as Stock Dips, Ark Keeps Offloading AMD Shares - Sahm
Cathie Wood’s ARK sells BioNTech and buys SpaceX stock - Investing.com
10 Newly Overvalued Stocks this Week - Morningstar
BioNTech’s Factory Sell-Off and a Founder’s Spin-Off: Two Bets That Could Reshape the Stock - aktiencheck.de
PTC Therapeutics (PTCT) moves 7.2% higher: Will this strength last? - MSN
MRNA Stock on the Move: What Sparked the 33.5% Jump in the Past Week? - TradingView
European ADRs Jumped As Biotech Led The Pack - Finimize
BioNTech SE ADR (BNTX) News Today: Latest Market and Industry Updates - Traders Union
BioNTech stock trades down as founders leave the company, raising transition concerns - Traders Union
Comirnaty Omicron-adapted formulation from BioNTech SEupdated mRNA shot for the 2024-25 season - ad-hoc-news.de
Enterprise value to revenue forward of BioNTech SE Sponsored ADR – BSESOF:22UA - TradingView
BioNTech SE Sponsored ADR Actuals & Estimates (NASDAQ:BNTX) - TradingView
Price to sales forward of BioNTech SE Sponsored ADR – BSESOF:22UA - TradingView
Enterprise value to EBIT forward of BioNTech SE Sponsored ADR – BSESOF:22UA - TradingView
BioNTech’s Oncology Transformation Hinges on Dense Second-Half Data Flow () - aktiencheck.de
BioNTech (BNTX) 10K Form and Latest SEC Filings 2026 - MarketBeat
Price to earnings forward of BioNTech SE Sponsored ADR – BSESOF:22UA - TradingView
Ubiquiti Upgraded, Reddit Downgraded: Updated Rankings on Top Blue-Chip Stocks - Yahoo Finance
BioNTech's €16.8 Billion Cash Hoard Is the Prize as Moderna Circles Factories and Spin-Off Looms - aktiencheck.de
Why BioNTech’s BNT316/ ONC-392 could quietly change lung cancer care - Ad-hoc-news.de
PTC Therapeutics (PTCT) Moves 7.2% Higher: Will This Strength Last? - Yahoo Finance
BioNTech Faces Shareholder Revolt Over Spin-Off Even as It Prepares First US Cancer Filing - aktiencheck.de
BioNTech Slashes 1,800 Jobs and Kicks Off $1 Billion Buyback in Oncology Push () - aktiencheck.de
BioNTech SE Stock (US09075V1026): Buyback And Oncology Pipeline Keep Shares In Focus - Ad-hoc-news.de
BioNTech Stands at a Pivotal Juncture as First FDA Filing Approaches and Pipeline Data Piles Up - aktiencheck.de
Moderna Says New COVID Vax Doesn't Infringe BioNTech IP - Law360
BioNTech's $1 Billion Buyback Marches Forward as Founders Exit and Cancer Trials Intensify - aktiencheck.de
BioNTech Has $16.8 Billion in Cash, a $1 Billion Buyback, and Promising Cancer Data — So Why Is the Stock Stuck? - aktiencheck.de
BioNTech: When Pipeline Progress Meets a Market That Demands Revenue () - aktiencheck.de
Comirnaty COVID-19 Vaccine: What Matters Now for US Patients - AD HOC NEWS
Bristol-Myers Upgraded, Broadcom Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
BioNTech’s Pipeline Pivot Meets a Market That Won’t Look Up () - aktiencheck.de
BioNTech Stock: A Week of Crosscurrents Where Macro and a Medical Congress Collide () - aktiencheck.de
BioNTech Faces Twin Headwinds: Analyst Divergence and German Health Overhaul () - aktiencheck.de
Bernstein reiterates BioNTech stock rating on pumitamig risks - Investing.com
BioNTech's Oncology Momentum Clashes With Berlin's Health-Cost Crackdown () - aktiencheck.de
BioNTech’s Costly Pivot: Cancer Pipeline Promises Meet Political and Financial Realities () - aktiencheck.de
Opportunities in the Oncology Market: Positioning for the Next Billion-Dollar Catalyst with BioNTech, Vidac Pharma, and Pfizer - news.financial
BioNTech's ASCO Data Showcase Two Late-Stage Hopes Amid Cost Cuts and a $1 Billion Buyback - aktiencheck.de
BNTX Technical Analysis | Trend, Signals & Chart Patterns | BIONTECH SE-ADR (NASDAQ:BNTX) - ChartMill
BioNTech Races Toward First Oncology Approval as ASCO Data Bolsters Pipeline Credibility - aktiencheck.de
BNTX Stock Quote Price and Forecast - CNN
Pumitamig’s 72.7% Response at Reduced Dose Reshapes BioNTech’s Oncology Ambitions () - aktiencheck.de
BioNTech’s ASCO Data Blitz Fails to Close Analyst Split as First FDA Filing Looms () - aktiencheck.de
BioNTech Juggles Vaccine Tweaks and Cancer Milestones as Investors Look Beyond COVID - aktiencheck.de
BioNTech Shows Its Hand at ASCO: A Pipeline in Full Bloom and a Radical Cost Overhaul () - aktiencheck.de
BNTXBioNTech SE ADR Dividends - Finviz
BioNTech upgraded to “buy” at UBS as next-gen cancer drugs de-risk - Investing.com
Caution with BioNTech! Novo Nordisk Accelerates! Buying Opportunity in Vidac Pharma Stock? - news.financial
BioNTech Grapples With Labor Strife and Analyst Skepticism as Stock Languishes () - aktiencheck.de
BioNTech’s ASCO Runway: Dual Cancer Data, a Shifting Analyst Pulse, and a Cash-Rich Pause for Growth - aktiencheck.de
BioNTech Faces Twin Test: Labor Strife Over 1,860 Jobs Meets ASCO’s Clinical Verdict () - aktiencheck.de
BioNTech Unveils $1B Buyback While Bernstein Flags Approval Risk Ahead of Oncology Data Dump - aktiencheck.de
BioNTech’s ctDNA Colorectal Cancer Study Signals Next Steps in Its Oncology Strategy - TipRanks
0.80%
2.11%
大文字化:
|
ボリューム (24 時間):